Therapeutic Pipeline

ABBV-RGX-314 is our product candidate for the treatment of wet age-related macular degeneration (AMD). ABBV-RGX-314 is being developed as a novel, one-time treatment for wet AMD that includes the NAV® AAV8 vector containing a gene encoding for a monoclonal anti-VEGF antibody fragment.

ABBV-RGX-314 is our product candidate for the treatment of wet age-related macular degeneration (AMD). ABBV-RGX-314 is being developed as a novel, one-time treatment for wet AMD that includes the NAV® AAV8 vector containing a gene encoding for a monoclonal anti-VEGF antibody fragment.

ABBV-RGX-314 is our product candidate for the treatment of diabetic retinopathy. ABBV-RGX-314 is being developed as a novel, one-time treatment that includes the NAV® AAV8 vector containing a gene encoding for a monoclonal anti-VEGF antibody fragment.

RGX-202 is our product candidate for the treatment of Duchenne muscular dystrophy and is designed to use our NAV® AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal domain found in naturally occurring dystrophin.

RGX-121 is designed to use the NAV® AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.